<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002751</url>
  </required_header>
  <id_info>
    <org_study_id>QRIVS-001</org_study_id>
    <secondary_id>PAR 20-292</secondary_id>
    <secondary_id>PAR 20-292</secondary_id>
    <nct_id>NCT05002751</nct_id>
  </id_info>
  <brief_title>Quantifying Radiation Induced Vaginal Stenosis</brief_title>
  <acronym>QRIVS</acronym>
  <official_title>Quantifying Radiation Induced Vaginal Stenosis for the Development of a Novel Dilator Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation (RT) affects the vagina by narrowing, tightening and scarring, termed vaginal&#xD;
      stenosis (VS). VS occurs in up to 88% of patients treated with radiation for cervical cancer.&#xD;
      VS is not well characterized in measurements. There is a lack of understanding of how short&#xD;
      and tight the vagina becomes after RT. This study will use specific measurements of the&#xD;
      vagina during the routine physician physical exam after RT in the follow up periods: after&#xD;
      RT, 3 months, 6 months, and 12 months using a plastic commercial dilator set and length and&#xD;
      width measurements.&#xD;
&#xD;
      In addition, the study use a validated sexual health survey and a specific survey on vaginal&#xD;
      dilation preferences to help stop VS after RT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-arm pilot will enroll 12 subjects scheduled to receive radiotherapy or&#xD;
      brachytherapy for gynecological cancers. The study will collect data from CT images, physical&#xD;
      measurements, patient reported outcomes to develop a quantifiable generalizable metric for&#xD;
      determining the severity of radiotherapy/brachytherapy induced vaginal stenosis.&#xD;
&#xD;
      The data will be used to inform the development of a novel personalized device for the&#xD;
      treatment of vaginal stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify radiation induced vaginal stenosis</measure>
    <time_frame>1.5 years</time_frame>
    <description>acquire and integrate imaging and direct patient vaginal diameter measurements to characterize VS for the computer and benchtop models</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acquire Patients' Treatment Concerns and Preferences</measure>
    <time_frame>1.5 years</time_frame>
    <description>Using a series of sexual and vaginal health questionnaires presenting an array of scaled (quantified) options we will determine patients' perceived flaws about current treatment and their preferences, and integrate them with the VS measurement results of Aim1 to guide modification and optimization of our soft balloon VS treatment system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimize and Validate Vaginal Stenosis Treatment System</measure>
    <time_frame>1 year</time_frame>
    <description>Incorporating the multimodal vaginal stenosis measurements and patient preferences acquired in Aim 1, we will use computer modelling based on known vaginal wall properties to simulate and predict the long-term outcomes of balloon-driven, graded vaginal expansion to counteract VS. Benchtop experimentation will utilize an inflatable balloon-type device and 3D printed biomimetic stenosed vaginal phantoms to test the proposed treatment effect over various time periods emulating different stages of fibrotic stenosis. To directly test our working hypothesis results acquired from modeling will be compared statistically to benchtop data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Vaginal Stricture</condition>
  <condition>Vaginal Stenosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>1. Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>UCSD Vaginal Dilator Questionnaire</intervention_name>
    <description>14 question survey</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC Sexual Health Questionnaire</intervention_name>
    <description>22 question survey</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female subjects over 18 years old, scheduled to receive radiotherapy and/or brachytherapy&#xD;
        for the treatment of gynecological cancers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed newly diagnosed advanced cervical cancer&#xD;
             (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009&#xD;
             clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages&#xD;
             IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN&#xD;
             nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy&#xD;
             or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.&#xD;
&#xD;
          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix II).&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               1. leukocytes ≥2,500/mcL&#xD;
&#xD;
               2. absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               3. platelets ≥100,000/mcL&#xD;
&#xD;
               4. hemoglobin ≥8 g/dL (can be transfused with red blood cells pre- study)&#xD;
&#xD;
               5. total bilirubin ≤1.5 × institutional upper limit of normal (ULN)&#xD;
&#xD;
               6. AST(SGOT)/ALT(SGPT) ≤3 × ULN&#xD;
&#xD;
               7. alkaline phosphatase ≤2.5 × ULN&#xD;
&#xD;
               8. creatinine &lt;1.5 mg/dL INR and aPTT ≤1.5 × ULN (This applies only to patients who&#xD;
                  do not receive therapeutic anticoagulation; patients receiving therapeutic&#xD;
                  anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a&#xD;
                  stable dose.)&#xD;
&#xD;
          -  Age is &gt; 18 years.&#xD;
&#xD;
          -  Patient does not have a known allergy to cisplatin or compounds of similar biologic&#xD;
             composition.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Patients positive for human immunodeficiency virus (HIV) are allowed on study, but&#xD;
             HIV-positive patients must have:&#xD;
&#xD;
          -  A stable regimen of highly active anti-retroviral therapy (HAART)&#xD;
&#xD;
          -  No requirement for concurrent antibiotics or antifungal agents for the prevention of&#xD;
             opportunistic infections&#xD;
&#xD;
          -  A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard&#xD;
             PCR-based tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received prior radiation therapy to the pelvis or abdominal cavity,&#xD;
             PALN radiation, or previous therapy of any kind for this malignancy or pelvic, PALN,&#xD;
             or abdominal radiation for any prior malignancy.&#xD;
&#xD;
          -  Patients with PALN nodal metastasis above the T12/L1 interspace.&#xD;
&#xD;
          -  Patients who had a radical hysterectomy with positive PALNs are not eligible.&#xD;
&#xD;
          -  Patients with prior allogeneic bone marrow transplantation or prior solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients previously treated with systemic anticancer therapy (e.g., chemotherapy,&#xD;
             targeted therapy, immunotherapy) within 3 years prior to entering the study.&#xD;
&#xD;
          -  Patients diagnosed on imaging or biopsy with a synchronous primary malignancy (with&#xD;
             the exception of DCIS of the breast, or early stage basal cell carcinoma of the skin)&#xD;
&#xD;
             a. transcription mediated amplification (TMA) or branched DNA testing.&#xD;
&#xD;
          -  History or risk of autoimmune disease, including but not limited to systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Mayadev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego Moores Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerald Henderson, BA</last_name>
    <phone>858-534-4811</phone>
    <email>gehenderson@health.ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jyoti Mayadev, MD</last_name>
    <email>jmayadev@health.ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jyoti Mayadev, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Vaginal Stenosis</keyword>
  <keyword>Vaginal Stricture</keyword>
  <keyword>Radiotherapy Side Effect</keyword>
  <keyword>Brachytherapy Side Effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

